Suppr超能文献

揭示新冠病毒对类风湿关节炎的影响:来自罗马尼亚两家医院的见解——初步结果

Unraveling the Impact of COVID-19 on Rheumatoid Arthritis: Insights from Two Romanian Hospitals-Preliminary Results.

作者信息

Vlădulescu-Trandafir Andreea-Iulia, Onose Gelu, Munteanu Constantin, Iancu Ioana, Bălănescu Andra-Rodica, Opriș-Belinski Daniela, Berghea Florian, Prefac Cristiana, Grădinaru Elena, Aurelian Sorina, Ciobanu Vlad, Bojincă Violeta-Claudia

机构信息

Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 020022 Bucharest, Romania.

Neuromuscular Rehabilitation Clinic Division, Teaching Emergency Hospital "Bagdasar-Arseni", 041915 Bucharest, Romania.

出版信息

Biomedicines. 2024 Sep 21;12(9):2145. doi: 10.3390/biomedicines12092145.

Abstract

BACKGROUND

Rheumatoid arthritis (RA) patients are at heightened risk of Coronavirus Disease-19 (COVID-19) complications due to immune dysregulation, chronic inflammation, and treatment with immunosuppressive therapies. This study aims to characterize the clinical and laboratory parameters of RA patients diagnosed with COVID-19, identify predictive risk factors for severe forms of this infection for RA patients, and determine if any RA immunosuppressive therapy is associated with worse COVID-19 outcomes.

METHODS

A retrospective observational case-control study included 86 cases (43 diagnosed with RA and 43 cases without any inflammatory or autoimmune disease) that suffered from SARS-CoV-2 in two Romanian hospitals between March 2020 and February 2024. Data on demographics, RA disease characteristics, COVID-19 severity, treatment regimens, and outcomes were analyzed.

RESULTS

RA patients exhibited a distinct symptom profile compared to non-RA controls, with higher incidences of neurological, musculoskeletal, and gastrointestinal symptoms, while the control group showed more respiratory and systemic manifestations. Severe COVID-19 is correlated with age and laboratory markers like erythrocyte sedimentation rate (ESR), leucocytes, neutrophils, neutrophil-to-lymphocyte ratio (NLR), aspartate aminotransferase (AST), serum creatinine, and urea. Additionally, RA treatments, particularly rituximab (RTX), were associated with more severe COVID-19 outcomes (but with no statistical significance), potentially due to the advanced disease stage and comorbidities in these patients. Post-infection, a significant number of RA patients experienced disease flares, necessitating adjustments in their treatment regimens.

CONCLUSIONS

This study underscores the complex interplay between RA and COVID-19, highlighting significant clinical heterogeneity and the need for tailored management strategies. Limitations include sample size constraints, possible selection, and information bias, as well as the lack of adjustments for potential confounding variables that hinder the ability to formulate definitive conclusions. Future research plans to expand the research group size and further elucidate these relationships.

摘要

背景

类风湿关节炎(RA)患者由于免疫失调、慢性炎症以及免疫抑制疗法的使用,感染新型冠状病毒肺炎(COVID-19)后出现并发症的风险更高。本研究旨在描述确诊为COVID-19的RA患者的临床和实验室参数,确定RA患者发生严重感染形式的预测风险因素,并确定RA免疫抑制疗法是否与更差的COVID-19预后相关。

方法

一项回顾性观察病例对照研究纳入了2020年3月至2024年2月期间在罗马尼亚两家医院感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的86例患者(43例确诊为RA,43例无任何炎症或自身免疫性疾病)。分析了人口统计学、RA疾病特征、COVID-19严重程度、治疗方案和预后的数据。

结果

与非RA对照组相比,RA患者表现出不同的症状特征,神经、肌肉骨骼和胃肠道症状的发生率更高,而对照组表现出更多的呼吸道和全身表现。严重COVID-19与年龄以及红细胞沉降率(ESR)、白细胞、中性粒细胞、中性粒细胞与淋巴细胞比值(NLR)、天冬氨酸转氨酶(AST)、血清肌酐和尿素等实验室指标相关。此外,RA治疗,尤其是利妥昔单抗(RTX),与更严重的COVID-19预后相关(但无统计学意义),这可能是由于这些患者疾病分期较晚和合并症较多。感染后,大量RA患者出现病情复发,需要调整治疗方案。

结论

本研究强调了RA与COVID-19之间复杂的相互作用,突出了显著的临床异质性以及制定个性化管理策略的必要性。局限性包括样本量限制、可能的选择和信息偏倚,以及缺乏对潜在混杂变量的调整,这妨碍了得出明确结论的能力。未来的研究计划扩大研究组规模并进一步阐明这些关系。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f75/11430409/e2893106dd7b/biomedicines-12-02145-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验